ALT (Altimmune, Inc.) Stock Financials & Earnings | Market Cap Arena

ALT (Altimmune, Inc.) Stock Financials & Earnings | Market Cap Arena

ALTAltimmune, Inc.

Mkt Cap$353M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$41,000

Net Income (TTM)-$88M

EPS (TTM)-$1.01

Free Cash Flow (TTM)-$68M

Gross Margin-36451.2%

Op. Margin-230461.0%

Net Margin-214861.0%

FCF Margin-165473.2%

P/S Ratio (TTM)8599.7x

P/E Ratio (TTM)—

YoY Rev Growth+105.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$21K	$21K	-$22M
Q2 23	$6K	-$13M	-$18M
Q3 23	$362K	-$18M	-$23M
Q4 23	$37K	$37K	-$34M
Q1 24	$5K	-$102K	-$27M
Q2 24	$5K	$5K	-$27M
Q3 24	$5K	$5K	-$25M
Q4 24	$5K	$5K	-$25M
Q1 25	$5K	$5K	-$22M
Q2 25	$5K	$5K	-$23M
Q3 25	$5K	-$15M	-$21M
Q4 25	$26K	$0	-$29M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	1263.8x	—
Q4 23	827.7x	—
Q1 24	860.0x	—
Q2 24	862.1x	—
Q3 24	6780.5x	—
Q4 24	17629.4x	—
Q1 25	17629.4x	—
Q2 25	17629.4x	—
Q3 25	17629.4x	—
Q4 25	8599.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$19M	-$19M
Q2 23	-$20M	-$20M
Q3 23	-$20M	-$20M
Q4 23	-$17M	-$17M
Q1 24	-$16M	-$16M
Q2 24	-$18M	-$18M
Q3 24	-$27M	-$27M
Q4 24	-$18M	-$18M
Q1 25	-$17M	-$17M
Q2 25	-$20M	-$20M
Q3 25	-$12M	-$12M
Q4 25	-$19M	-$19M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$51K
Q2 23	$4K
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$10K
Q3 25	$0
Q4 25	$1K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-34.4%	+11.5%
Q2 23	-25.0%	-11.7%
Q3 23	+18000.0%	-7.5%
Q4 23	+133.6%	+46.4%
Q1 24	-76.2%	+23.0%
Q2 24	-16.7%	+48.5%
Q3 24	-98.6%	+8.2%
Q4 24	-86.5%	-26.1%
Q1 25	+0.0%	-18.6%
Q2 25	+0.0%	-14.3%
Q3 25	+0.0%	-15.8%
Q4 25	+420.0%	+16.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$3M	12738.1%
Q2 23	$0	0.0%
Q3 23	$3M	748.6%
Q4 23	$2M	6673.0%
Q1 24	$4M	73000.0%
Q2 24	$4M	86220.0%
Q3 24	$3M	61560.0%
Q4 24	$3M	67080.0%
Q1 25	$4M	80300.0%
Q2 25	$0	0.0%
Q3 25	$4M	71080.0%
Q4 25	$5M	19003.8%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$17M	$5M
Q2 23	$13M	$5M
Q3 23	$18M	$5M
Q4 23	$17M	$4M
Q1 24	$21M	$5M
Q2 24	$21M	$6M
Q3 24	$20M	$5M
Q4 24	$20M	$5M
Q1 25	$16M	$6M
Q2 25	$17M	$6M
Q3 25	$15M	$6M
Q4 25	$18M	$11M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$105M	$61M	$166M
Q2 23	$102M	$58M	$160M
Q3 23	$87M	$54M	$141M
Q4 23	$135M	$63M	$198M
Q1 24	$79M	$103M	$182M
Q2 24	$57M	$108M	$165M
Q3 24	$31M	$108M	$139M
Q4 24	$37M	$95M	$132M
Q1 25	$49M	$101M	$150M
Q2 25	$183M	$0	$183M
Q3 25	$61M	$150M	$211M
Q4 25	$44M	$230M	$273M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	50M	+0.2%
Q2 23	51M	+1.1%
Q3 23	54M	+5.8%
Q4 23	58M	+9.0%
Q1 24	71M	+21.1%
Q2 24	71M	+0.2%
Q3 24	71M	+0.2%
Q4 24	71M	+0.2%
Q1 25	76M	+6.0%
Q2 25	81M	+7.8%
Q3 25	89M	+9.7%
Q4 25	101M	+12.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$291K	35
FY 15	$967K	11
FY 16	$402K	13
FY 17	$1K	30
FY 18	$383K	27
FY 19	$232K	25
FY 20	$190K	43
FY 21	$94K	47
FY 22	-$1K	52
FY 23	$7K	59
FY 24	$339	59
FY 25	$0	200K